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Abstract Trypsin treatment of HeLa cells results in a limited
proteolysis of the coxsackievirus and adenovirus receptor (CAR)
after which the cleaved CAR remains cell-associated and tryptic
peptides remain associated through disulfide bonds. Trypsin-
treated HeLa cells remain susceptible to infection with coxsack-
ievirus B and produce progeny virus at 8 h post-infection in
amounts comparable to cells with intact CAR. HeLa cells
remove the proteolysed CAR within 15 h and require over 24 h to
restore intact CAR to control levels. As turnover is relatively
slow, physiological functions that require intact CAR protein
may be compromised for more than 24 h following trypsin
treatment. Moreover, since removal of proteolysed CAR
proceeds at more than twice the replacement rate, trypsin
treatment disrupts the receptor-per-cell steady state for at least
24 h. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
B group coxsackieviruses (CVB) and adenoviruses share a
single protein as the cell surface viral receptor (coxsackievirus
and adenovirus receptor; CAR) [1^3]. The CAR protein has
been well characterized at the molecular level, including the
structure of the Ad-binding domain associated with the Ad
¢ber knob [4]. There is scant information regarding CAR cell
biology, however, and the physiological function of CAR is
unknown. Since CAR is a principal factor involved in gene
therapy e¡orts using Ad2- and Ad5-based vectors, as well as
e¡orts to develop CVB-based vaccines, knowledge of CAR
cell biology and function is fundamentally important to future
applications of these viruses.
Experiments conducted before isolation of CAR found that
the binding of CVB to HeLa cells is not altered by trypsin
treatment [5^7], and in vitro experiments often use cultured
cells exposed to virus only hours after subculture with trypsin.
The experiments reported here reveal that CAR is not resis-
tant to trypsin, and treatment of HeLa cells with trypsin alters
the expression of this viral receptor.
2. Materials and methods
HeLa cells were grown in DMEM with 10% fetal calf serum, glu-
tamine, penicillin, streptomycin, and gentamicin. To determine the
e¡ects of trypsin on CAR, con£uent cell monolayers in T25 £asks
were rinsed (U3) and covered with 2 ml DMEM. Trypsin (TPCK
trypsin, 1 mg/ml) or DMEM (1 ml) was added. After 15 min at
37‡C, 100 ul phenylmethylsulfonyl£uoride (PMSF; 80 nM) and N-
ethylmaleimide (NEM; 200 nM) in ethanol, and 0.5 ml soybean tryp-
sin inhibitor (SBTI; 5 mg/ml in DMEM) were added. Adherent cells
were scraped loose and cells were collected by centrifugation (Sorval
RT11B 15 min, 1500 rpm). Cells were lysed with 1 ml 2% (w/v) octyl
glucoside in 0.01 M Tris, 0.1 M NaCl, pH 7.6 (TBS) containing 2 mM
PMSF and 5 mM NEM. Lysates were collected after centrifugation
(15 min, 2500 rpm) and 5 ml cold acetone was added. Precipitated
proteins were dissolved in 3U Laemmli SDS solvent [8] with (reduced)
or without (not reduced) 60 mM dithiothreitol (DTT). Western blots
were probed with MoAb.E1, which recognizes an epitope in the C2-
like domain of CAR, and analyzed as described [9].
To assess CAR synthesis and turnover following trypsin treatment,
con£uent cultures of HeLa cells in T25 £asks were washed two times
with DMEM and covered with 1 ml DMEM. Trypsin (1 ml) was
added to 0.5 mg/ml. A control sample was treated in parallel without
trypsin. After 15 min at 37‡C, 0.5 ml SBTI (5 mg/ml in DMEM) was
added, followed by 5 ml DMEM^10% FCS. The medium was re-
moved and centrifuged (10 min, 1200 rpm). The pelleted cells were
resuspended in 5 ml DMEM^10% FCS and returned to the T25
£asks. At timed intervals, PMSF and NEM were added to the £asks
and adherent cells were scraped loose, washed with TBS (containing
2 mM PMSF and 5 mM NEM) and prepared for analysis of CAR in
the cell lysates. Aliquots of the ¢nal wash were used to determine the
protein concentration (BCA assay, Pierce) of each sample. Equal
amounts of protein from each sample were loaded on the polyacryl-
amide gel and CAR was detected on Western blots.
To determine whether trypsin digestion of CAR altered HeLa per-
missivity to CVB, HeLa cells were grown to con£uence in T25 £asks.
Flasks with and without trypsin treatment were inoculated with
CVB3/0 [10] for 25 min, washed with medium, and returned to the
37‡C incubator. Eight hours later, the cells were frozen and thawed to
release virus and scraped from the £asks. Following centrifugation,
supernatants were collected for titer determination and cellular mate-
rial in the pellet was taken for Western blot analysis of CAR expres-
sion.
3. Results
To evaluate the susceptibility of cell surface CAR to pro-
teolysis by trypsin, HeLa cells were grown to con£uence,
treated with trypsin, harvested, and lysed with octyl glucoside.
Controls were processed in parallel without trypsin treatment.
The immunoblots revealed that trypsin treatment produced no
discernible e¡ect on the size of CAR when analyzed without
reduction (Fig. 1, lanes 1 and 2), but treatment with dithio-
threitol (DTT) released an immunoreactive peptide of Mr
21 000^24 000 (Fig. 1, lane 6, arrow), with signi¢cant loss of
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reactivity in the parental band. This result shows that trypsin
treatment of HeLa cells results in a limited proteolysis of
CAR, and the labile bonds must be located within disul¢de
loops such that, in the absence of reduction, no peptides are
lost from the digested protein and the peptides remain cell-
associated. To provide additional information concerning lo-
cation of the epitope reactive with MoAb.E1 and sites cleaved
by trypsin, RDt3 cells were used in similar experiments. RDt3
cells were derived from the CAR-negative RD cell line by
transfection with a cytoplasmic domain-deleted cDNA de-
rived from CAR cDNA. The construct (HCARt3) contains
the human CAR signal sequence and residues Leu-1 through
Lys-243, with an irrelevant 39-residue extension contributed
by the plasmid polylinker sequence. RDt3 cells are susceptible
to infection with CVB and the truncated HCARt3 is recog-
nized by MoAb.E1 [9]. Trypsin treatment of the RDt3 cells
produced a limited proteolysis, generating an immunoreactive
peptide with the same electrophoretic mobility as that ob-
served with trypsin-treated HeLa cells (Fig. 1, lane 8). This
¢nding indicates that the tryptic peptide from both CAR and
HCARt3 that is reactive with MoAb.E1 cannot include the
cytoplasmic domain. Thus, at least one tryptic cleavage must
occur within a disul¢de loop of the C2-like domain. The mass
of the immunoreactive tryptic peptide is consistent with a
single proteolytic cleavage near the middle of the C2-like do-
main (between Cys-143 and Cys-193, numbered using Gen-
Bank sequence Y07593 and amino-terminal leucine [2]), or
two cleavages ^ one near the middle of the V-like domain
(between Cys-22 and Cys-101) and another in the last third
of the C2-like domain (between Cys-143 and Cys-204). In
other experiments, a transient band near Mr 40 000 has been
detected (e.g. Fig. 2, lanes 4^6) that appears to be an inter-
mediate product which precedes appearance of the Mr 21 000^
24 000 product. This observation is consistent with the two-
event model for proteolytic derivation of the Mr 21 000^24 000
product.
Further experiments determined that trypsin at 0.33 to 0.5
mg/ml was su⁄cient to digest most or all of the CAR ex-
pressed on con£uent HeLa cells within 15 min (Fig. 2), and
15 min with trypsin at 0.5 mg/ml was used in subsequent
experiments. Extended trypsin treatment diminishes the im-
munoreactive peptide product, indicating that additional pro-
teolysis occurs with destruction of the epitope recognized by
MoAb.E1.
The ability to detect native CAR as well as its tryptic prod-
uct enabled experiments to determine the time-course of CAR
replacement by new protein, as well as clearance of the di-
gested CAR. Con£uent cultures of HeLa cells were digested
with trypsin (control received no trypsin) and harvested for
CAR analysis at various times after replating. CAR was
quantitated relative to serial dilutions of the untreated control
[9], and representative blots are shown in Fig. 3. Results from
multiple experiments were combined to estimate the rates at
which new CAR was expressed (Fig. 4A). Loss of the 21^24
kDa peptide was quantitated relative to the maximum amount
present in each of three experiments (Fig. 4B). The data in
Fig. 4A indicate that CAR was replaced at an average of 3.2%
( þ 0.4) per hour, reaching 50% of control levels about 16 h
Fig. 2. CAR in con£uent HeLa cells before (lane 1) or after treat-
ment with trypsin at 0.1 mg/ml (lanes 2 and 3) or 0.33 mg/ml (lanes
4^6) for 1 min (lane 4), 5 min (lanes 2 and 5) or 15 min (lanes 3
and 6). All samples were reduced.
Fig. 3. CAR synthesis and turnover following trypsin treatment.
Two experiments are shown. In the upper panel, samples 5^8 corre-
spond to the untreated control (5) and two-fold serial dilutions (6^
8). Lanes 1^4 contained samples prepared 20.7, 12, 5.6, and 0 h
after trypsin treatment, respectively. The arrow points to the 21^24
kDa tryptic peptide recognized by MoAb.E1. In the lower panel,
samples 6^9 correspond to the untreated control (6) and serial two-
fold dilutions to provide a standard curve for quantitative analysis
(7^9). Lanes 1^5 contained samples prepared 24.3, 13, 9.2, 3.9, and
0 h after trypsin treatment, respectively.
Fig. 1. CAR in HeLa (lanes 1, 2, 5 and 6) and RDt3 cells (lanes 3,
4, 7 and 8) analyzed before (odd numbered) and after (even num-
bered) trypsin treatment. Samples in lanes 5^8 were reduced. Num-
bers on the left indicate the mass (in kDa) of marker proteins corre-
sponding to the positions marked with ‘-’.
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after trypsin treatment. The four experiments shown in panel
A gave very similar results, while a single experiment (not
shown) gave a slower rate of recovery. Removal of proteolyti-
cally cleaved CAR (detected as the 21^24 kDa proteolytic
peptide) was not linear with time, and the peptide was 50%
removed by about 6 h following trypsin treatment. These
results show that the cleaved receptor is removed from the
cell more rapidly than new CAR is expressed (Fig. 4A and
B). The di¡erent rates at which cleaved but functional recep-
tor is cleared and replaced by newly synthesized receptor
should produce a window during which minimum levels of
receptor are present, and this minimum can be predicted to
occur several hours after trypsin treatment. Fig. 4C, derived
by combining the curves in Fig. 4A and B, shows that if the
cleaved receptor is equivalent to 100% of CAR immediately
following trypsin treatment, receptor levels will decrease for
the ensuing 14 h to a nadir near 40% of control levels. This
nadir will be followed by recovery, reaching 100% of control
levels only after an additional 14 h or more. If the cleaved but
functional CAR immediately after trypsin treatment corre-
sponds to only 50% of the CAR present before trypsin treat-
ment, the nadir in receptor expression would occur at about
8 h post-trypsin.
To determine whether trypsin digestion of CAR altered
HeLa permissivity to CVB, HeLa cells with and without tryp-
sin treatment were inoculated with CVB3. Eight hours later,
CAR remained readily detectable in HeLa cells infected with
CVB3/0 in the absence of trypsin treatment (Fig. 5, lane 1),
which is consistent with the report that CVB infection does
not reduce CAR expression in endothelial cells [9]. In con-
trast, CAR remained markedly reduced in HeLa cells infec-
tion with CVB3 after treatment with trypsin (Fig. 5, lane 2),
indicating that synthesis of new host protein, which is blocked
soon after CVB infection, is required to re-express intact
CAR. A band near 40 kDa is pronounced in the sample
that was infected without trypsin treatment (Fig. 5, lane 1)
suggesting that proteolysis or some other modi¢cation of
CAR occurs during the infection. HeLa cells infected after
trypsin treatment produced CVB3 (1.58U108 TCID50) equiv-
alent to that obtained from HeLa cells that were not trypsin-
treated (1.58^2.11U108 TCID50), indicating that the infection
after limited proteolysis of CAR proceeds with e⁄ciency com-
parable to infection of cells bearing intact CAR.
4. Discussion
More than 30 years ago, Crowell and colleagues [5^7] re-
ported that CVB3 binding to HeLa cells was una¡ected by
trypsin treatment. Experiments reported here reveal that the
CAR is cleaved within 15 min following addition of trypsin to
HeLa cells. The limited proteolytic cleavage leaves CAR as-
sociated with the cell and the peptides remain associated
through disul¢de bonds. This altered protein appears to fully
support infection by CVB3. In contrast to the earlier work
showing that virus binding after treatment of HeLa cells with
chymotrypsin was 50% restored in about 4 h, the current
experiments found that 50% restoration of intact CAR pro-
tein following trypsin treatment required about 16 h. This
di¡erence may be due to the binding of CVB3 by multiple
proteins on the cell surface (e.g. DAF and CAR), whereas the
current experiments speci¢cally measured the CAR protein. It
is also noted that the di¡erent rates were determined after
treatment with di¡erent proteases which could potentially in-
Fig. 4. Synthesis of new CAR (A) and removal of trypsin-digested
CAR (B) from HeLa cells after treatment with trypsin. Panel C
shows the results of combining the curves in panels A and B.
Fig. 5. CAR in HeLa cells after 8 h infection with CVB3 with and
without trypsin treatment prior to inoculation. Lane 1: HeLa cells
infected with CVB3 without trypsin treatment. Lane 2: HeLa cells
treated with trypsin and inoculated with CVB3. Lane 3: HeLa cells
treated with trypsin and not infected.
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£uence the rate at which CAR is synthesized. Irrespective of
these di¡erences, full recovery of CVB3 binding after treat-
ment with chymotrypsin as well as expression of newly syn-
thesized CAR in trypsin-treated HeLa cells requires more
than 24 h after removal of the protease. Pertinent to contem-
porary studies of CAR and CVB infection, these observations
suggest that polarized epithelial cells in which CAR is not
accessible to virus [11] should be readily infectable after tryp-
sinization, even though the CAR will be altered. Furthermore,
results from the kinetic analyses of CAR expression after pro-
teolysis caution that studies that may be in£uenced by recep-
tor density or by residual proteolytically altered CAR should
be conducted at least 24 h after passaging cells using trypsin.
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